...
首页> 外文期刊>Bulletin of the Korean Chemical Society >Development of Cholinesterase Inhibitors Using (a)-Lipoic Acid-benzyl Piperazine Hybrid Molecules
【24h】

Development of Cholinesterase Inhibitors Using (a)-Lipoic Acid-benzyl Piperazine Hybrid Molecules

机译: a )-硫辛酸-苄基哌嗪杂化分子开发胆碱酯酶抑制剂

获取原文
   

获取外文期刊封面封底 >>

       

摘要

A series of hybrid molecules between (α)-lipoic acid (ALA) and benzyl piperazines were synthesized and their in vitro cholinesterase [acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE)] inhibitory activities were evaluated. Even though the parent compounds did not show any inhibitory activity against cholinesterase (ChE), all hybrid molecules showed BuChE inhibitory activity. Some hybrid compounds also displayed AChE inhibitory activity. Specifically, ALA-1-(3-methylbenzyl)piperazine (15) was shown to be an effective inhibitor of both BuChE (IC50 = 2.3 ± 0.7 μM) and AChE (IC50 = 30.31 ± 0.64 μM). An inhibition kinetic study using compound 15 indicated a mixed inhibition type. Its binding affinity (Ki) value to BuChE is 2.91 ± 0.15 μM.
机译:合成了一系列(α)-硫辛酸(ALA)和苄基哌嗪之间的杂合分子,并评估了其体外胆碱酯酶[乙酰胆碱酯酶(AChE)和丁酰胆碱酯酶(BuChE)]的抑制活性。即使母体化合物对胆碱酯酶(ChE)没有任何抑制活性,所有杂合分子均显示BuChE抑制活性。一些杂合化合物还显示出AChE抑制活性。具体而言,ALA-1-(3-甲基苄基)哌嗪(15)被证明是BuChE(IC50 = 2.3±0.7μM)和AChE(IC50 = 30.31±0.64μM)的有效抑制剂。使用化合物15的抑制动力学研究表明是混合抑制类型。它与BuChE的结合亲和力(Ki)值为2.91±0.15μM。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号